Aerosoliserat DNase for Treatment of Respiratory Failure in Severe COVID-19

Overview

Recent observations have suggested a role of neutrophil extracellular traps (NETs) in the pathophysiology of severe COVID-19. The aim of the study is to assess efficacy and safety of aerosolized DNase I to remove NETs and decrease respiratory distress in patients with COVID-19.

Full Title of Study: “Aerosoliserat DNase for Treatment of Respiratory Failure in Severe COVID-19 – a Phase 2, Single-blinded, Randomized Study”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Participant)
  • Study Primary Completion Date: December 1, 2022

Detailed Description

Study objectives: Primary objective: To compare the treatment effect of aerosolized DNase I to that of placebo (NaCl, 0.9%) on time to cessation of oxygen therapy or discharge from hospital in hospitalized patients with COVID-19 and respiratory dysfunction. Secondary objectives: To compare the treatment effect of aerosolized DNase I to that of placebo (NaCl, 0.9%) on 28-day mortality, days alive and without ventilator treatment, days alive and without high flow nasal oxygen treatment (Optiflow), length of stay in the ICU, days alive and outside hospital, relapse of hypoxia, days alive and without need for supplemental oxygen, adverse reactions. Exploratory objectives: To compare the treatment effect of aerosolized DNase I to that of placebo (NaCl, 9%) on quantification of NETs in respiratory secretions and on the incidence of clinical thromboembolic events. Study design: Phase 2 open-label randomized controlled multicentre trial. The study period is 28 days from randomization. A long term follow-up on mortality and readmission will also be collected via patient medical records/registries at day 90, day 180, and day 360 after randomization.

Interventions

  • Drug: aerosolized DNase
    • DNase
  • Drug: NaCl
    • NaCl 0.9%, isotonic saline

Arms, Groups and Cohorts

  • Active Comparator: Aerosolized DNase I
  • Placebo Comparator: NaCl

Clinical Trial Outcome Measures

Primary Measures

  • Time to cessation of oxygen therapy DNase I to that of placebo (NaCl, 0.9%) on time to cessation of oxygen therapy hospitalized patients with COVID-19 and respiratory dysfunction.
    • Time Frame: 28 days
    • Number of Days to cessation of oxygen therapy after start of treatment

Secondary Measures

  • 28-day mortality
    • Time Frame: 28 days
    • Number of diseased patients up to 28 Days after start of treatment
  • Number of Days alive and without ventilator treatment
    • Time Frame: 28 days
    • Number of Days alive and without ventilator treatment up to 28 Days after start of treatment
  • Number of Days alive and without high flow nasal oxygen treatment (Optiflow)
    • Time Frame: 28 days
    • Number of Days alive and without high flow nasal oxygen treatment (Optiflow) up to 28 Days after start of treatment
  • Number of Days alive and free of stay in the ICU
    • Time Frame: 28 days
    • Number of Days alive and free of stay in the ICU up to 28 Days after start of treatment
  • Number of Days alive and outside hospital
    • Time Frame: 28 days
    • Number of Days alive and outside hospital up to 28 Days after start of treatment
  • Number of Days alive and free of a new episode and with oxygen saturation ≤93% after primary endpoint has been met
    • Time Frame: 28 days
    • Number of Days alive and free of a new episode and with oxygen saturation ≤93% after primary endpoint has been met up to 28 Days after start of treatment
  • Number of Days alive and without need of supplemental oxygen
    • Time Frame: 28 days
    • Number of Days alive and without need of supplemental oxygen up to 28 Days after start of treatment
  • Number of patients with adverse reactions
    • Time Frame: 28 days
    • Number of patients with adverse reactions reported up to 28 Days after start of treatment

Participating in This Clinical Trial

Inclusion Criteria

  • Age ≥18 years old – Admitted to hospital ward or ICU – A positive PCR test for SARS-CoV-2 from throat swab or nasopharynx – An oxygen saturation ≤90% after maximum 15 minutes without supplemental oxygen – Signed informed consent Exclusion Criteria:

  • Mental inability, reluctance or language difficulties that result in difficulty understanding the meaning of study participation – Known or suspected allergy against Pulmozyme – Chronic obstructive pulmonary disease stage III-IV or another comparable chronic respiratory disease – Participation in a clinical study with an investigational product during the last 30 days – Previous participation in this study – Pregnancy. Women of childbearing potential must agree to use contraceptives for the duration of the study period – Any condition that, in the opinion of the Investigator, would place the patient at increased risk or preclude the patient's compliance with the study

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Region Skane
  • Provider of Information About this Clinical Study
    • Principal Investigator: Adam Linder, senior concultant, associate professor – Region Skane
  • Overall Official(s)
    • Adam Linder, MD, Principal Investigator, Region Skåne
  • Overall Contact(s)
    • Adam Linder, MD, 004646171130, adam.linder@med.lu.se

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.